CELL DEATH DISCOV 润色咨询

Cell Death Discovery

出版年份:暂无数据 年文章数:928 投稿命中率: 开通期刊会员,数据随心看

出版周期:暂无数据 自引率:暂无数据 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2200214, encodeId=241d2200214d6, content=求好运,编辑和审稿人一生平安!!!<br><br>Manuscript Under Consideration 11th Apr 24 05:59:46<br>Editor Assigned 10th Apr 24 04:50:35<br>Manuscript Received 10th Apr 24 04:50:34, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230127/dd490db5809c41dba47efd8445d736af/b6403d79e2fb4308b2f2b14ee7a06741.jpg, createdBy=1f234693702, createdName=白衣13, createdTime=Wed Apr 24 22:07:15 CST 2024, time=2024-04-24, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2203732, encodeId=e3e72203e32b5, content=请问修改后的版本要怎么上传呢,我看邮件链接里没有可以上传修订后版本的地方, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbe18212751, createdName=ms4000000471597518, createdTime=Thu May 09 20:49:01 CST 2024, time=2024-05-09, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2150842, encodeId=10cf215084251, content=审稿速度:1.0<br>偏重的研究方向:非编码RNA与肿瘤<br>经验分享:投了小cdd一个月送审返回意见后被拒,自行补了一部分实验后转投这里 6.5 投稿 6.19 小修 7.13 补了实验返回去 7.18 原则性接收 7.20 改好格式返回 7.26 接收 7.28 proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2598527487, createdName=Terryzhong15, createdTime=Tue Aug 01 23:23:27 CST 2023, time=2023-08-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2122182, encodeId=cee2212218269, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:cell death disease被拒,23号转投Cell Death Discovery,27号就预接收了,让我一度怀疑是不是投了个假杂志。。。转投的时候我没有选reprint,不是知道是不是这个原因就只有一个审稿人,而且这个审稿人还是杂志社直接指派的,还发了邮件告知我。<br><br>ditorial decision: revise, reconsidered for publication in Cell Death Discovery<br>On 27 Mar, 2023<br>Review #1 received<br>Received 26 Mar, 2023<br>1 reviewer(s) invited<br>Invitations sent on 26 Mar, 2023<br>Reviewer #1 agreed<br>On 26 Mar, 2023<br>Submission checks complete<br>On 23 Mar, 2023<br>Submitted to Cell Death Discovery<br>On 23 Mar, 2023<br>Editor assigned<br>On 23 Mar, 2023<br>Transferred to Cell Death Discovery, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221212/08d68660ec5249d4951c3cf19104981b/d48862041d924877a2d8ff1dd10a565a.jpg, createdBy=881a5215169, createdName=todmo, createdTime=Tue Mar 28 08:16:52 CST 2023, time=2023-03-28, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2202035, encodeId=546622020355f, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:已经Manuscript Under Consideration 75 天了,等的好焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=87b62464712, createdName=12425381m24暂无昵称, createdTime=Mon May 06 18:29:27 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2188846, encodeId=a2db21888463f, content=2月5号投的,当天分配编辑并Under Consideration,现在投稿17天了还没有消息,大家最近都是多久送审或者被拒的呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLv3zmjYMzwQhcQkUYuJuQtVn1K9UfSHicAAqich642LF9jozKbFliaZw0tGbw3kSTrABiaD0O5JDHXXQ/132, createdBy=215e5309360, createdName=legendaryCYP, createdTime=Fri Feb 23 10:37:35 CST 2024, time=2024-02-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2167353, encodeId=b340216e35352, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:神经系统凋亡及机制<br>经验分享:更新一下投稿时间线:<br>Manuscript Received: 7.3<br>Editor Assigned :7.3<br>Manuscript Under Consideration: 7.4<br>Manuscript Under Consideration: 8.31<br>Decision Made: 9.2<br>Decision Sent to Author: 9.8 (一审65天,等的急啊;要求11.1前返回)<br>Manuscript Received: 10.18<br>Editor Assigned: 10.18<br>Manuscript Under Consideration: 10.19<br>目前返回20天了,research square状态还是 Submission checks complete,编辑还没有返回审稿人手里,要怎么办呀?要催吗?二审一般多久呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=58, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daea8237862, createdName=ms6000000748440029, createdTime=Wed Nov 08 10:04:15 CST 2023, time=2023-11-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2100036, encodeId=1276210003694, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:请问大家,Decision sent back to author后底部有一个<br>There are action items pending. Please click on the links next to the arrows .<br>Manuscript Tasks<br> Request Appeal<br> Check Status<br>这是什么意思,通讯作者也没有收到邮件,是拒稿了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3a515544947, createdName=ms3000001031683106, createdTime=Sat Nov 12 10:28:29 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239796, encodeId=6c781239e966f, content=审稿速度:6.0<br>经验分享:under consideration80天了,谁说这个快来着。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08542281224, createdName=121c6f2dm84(暂无昵称), createdTime=Fri Aug 19 19:39:59 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157541, encodeId=1ccd215e54134, content=偏重的研究方向:细胞死亡<br>经验分享:之前投小CDD送审后被拒建议转投小小CDD。半个月后编辑将之前的审稿意见再次返回来,建议根据审稿意见修改。因为上次有一份审稿意见并不是很理想加上面临毕业,所以比较担心。有没有相同经历的朋友可以分享一下经验呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fda95570287, createdName=MM---, createdTime=Wed Sep 13 16:40:57 CST 2023, time=2023-09-13, status=1, ipAttribution=宁夏)]
    2024-04-24 白衣13 来自伊利诺伊

    求好运,编辑和审稿人一生平安!!!

    Manuscript Under Consideration 11th Apr 24 05:59:46
    Editor Assigned 10th Apr 24 04:50:35
    Manuscript Received 10th Apr 24 04:50:34

    7

    展开7条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2200214, encodeId=241d2200214d6, content=求好运,编辑和审稿人一生平安!!!<br><br>Manuscript Under Consideration 11th Apr 24 05:59:46<br>Editor Assigned 10th Apr 24 04:50:35<br>Manuscript Received 10th Apr 24 04:50:34, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230127/dd490db5809c41dba47efd8445d736af/b6403d79e2fb4308b2f2b14ee7a06741.jpg, createdBy=1f234693702, createdName=白衣13, createdTime=Wed Apr 24 22:07:15 CST 2024, time=2024-04-24, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2203732, encodeId=e3e72203e32b5, content=请问修改后的版本要怎么上传呢,我看邮件链接里没有可以上传修订后版本的地方, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbe18212751, createdName=ms4000000471597518, createdTime=Thu May 09 20:49:01 CST 2024, time=2024-05-09, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2150842, encodeId=10cf215084251, content=审稿速度:1.0<br>偏重的研究方向:非编码RNA与肿瘤<br>经验分享:投了小cdd一个月送审返回意见后被拒,自行补了一部分实验后转投这里 6.5 投稿 6.19 小修 7.13 补了实验返回去 7.18 原则性接收 7.20 改好格式返回 7.26 接收 7.28 proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2598527487, createdName=Terryzhong15, createdTime=Tue Aug 01 23:23:27 CST 2023, time=2023-08-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2122182, encodeId=cee2212218269, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:cell death disease被拒,23号转投Cell Death Discovery,27号就预接收了,让我一度怀疑是不是投了个假杂志。。。转投的时候我没有选reprint,不是知道是不是这个原因就只有一个审稿人,而且这个审稿人还是杂志社直接指派的,还发了邮件告知我。<br><br>ditorial decision: revise, reconsidered for publication in Cell Death Discovery<br>On 27 Mar, 2023<br>Review #1 received<br>Received 26 Mar, 2023<br>1 reviewer(s) invited<br>Invitations sent on 26 Mar, 2023<br>Reviewer #1 agreed<br>On 26 Mar, 2023<br>Submission checks complete<br>On 23 Mar, 2023<br>Submitted to Cell Death Discovery<br>On 23 Mar, 2023<br>Editor assigned<br>On 23 Mar, 2023<br>Transferred to Cell Death Discovery, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221212/08d68660ec5249d4951c3cf19104981b/d48862041d924877a2d8ff1dd10a565a.jpg, createdBy=881a5215169, createdName=todmo, createdTime=Tue Mar 28 08:16:52 CST 2023, time=2023-03-28, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2202035, encodeId=546622020355f, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:已经Manuscript Under Consideration 75 天了,等的好焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=87b62464712, createdName=12425381m24暂无昵称, createdTime=Mon May 06 18:29:27 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2188846, encodeId=a2db21888463f, content=2月5号投的,当天分配编辑并Under Consideration,现在投稿17天了还没有消息,大家最近都是多久送审或者被拒的呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLv3zmjYMzwQhcQkUYuJuQtVn1K9UfSHicAAqich642LF9jozKbFliaZw0tGbw3kSTrABiaD0O5JDHXXQ/132, createdBy=215e5309360, createdName=legendaryCYP, createdTime=Fri Feb 23 10:37:35 CST 2024, time=2024-02-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2167353, encodeId=b340216e35352, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:神经系统凋亡及机制<br>经验分享:更新一下投稿时间线:<br>Manuscript Received: 7.3<br>Editor Assigned :7.3<br>Manuscript Under Consideration: 7.4<br>Manuscript Under Consideration: 8.31<br>Decision Made: 9.2<br>Decision Sent to Author: 9.8 (一审65天,等的急啊;要求11.1前返回)<br>Manuscript Received: 10.18<br>Editor Assigned: 10.18<br>Manuscript Under Consideration: 10.19<br>目前返回20天了,research square状态还是 Submission checks complete,编辑还没有返回审稿人手里,要怎么办呀?要催吗?二审一般多久呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=58, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daea8237862, createdName=ms6000000748440029, createdTime=Wed Nov 08 10:04:15 CST 2023, time=2023-11-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2100036, encodeId=1276210003694, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:请问大家,Decision sent back to author后底部有一个<br>There are action items pending. Please click on the links next to the arrows .<br>Manuscript Tasks<br> Request Appeal<br> Check Status<br>这是什么意思,通讯作者也没有收到邮件,是拒稿了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3a515544947, createdName=ms3000001031683106, createdTime=Sat Nov 12 10:28:29 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239796, encodeId=6c781239e966f, content=审稿速度:6.0<br>经验分享:under consideration80天了,谁说这个快来着。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08542281224, createdName=121c6f2dm84(暂无昵称), createdTime=Fri Aug 19 19:39:59 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157541, encodeId=1ccd215e54134, content=偏重的研究方向:细胞死亡<br>经验分享:之前投小CDD送审后被拒建议转投小小CDD。半个月后编辑将之前的审稿意见再次返回来,建议根据审稿意见修改。因为上次有一份审稿意见并不是很理想加上面临毕业,所以比较担心。有没有相同经历的朋友可以分享一下经验呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fda95570287, createdName=MM---, createdTime=Wed Sep 13 16:40:57 CST 2023, time=2023-09-13, status=1, ipAttribution=宁夏)]
    2024-05-09 ms4000000471597518 来自重庆

    请问修改后的版本要怎么上传呢,我看邮件链接里没有可以上传修订后版本的地方

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2200214, encodeId=241d2200214d6, content=求好运,编辑和审稿人一生平安!!!<br><br>Manuscript Under Consideration 11th Apr 24 05:59:46<br>Editor Assigned 10th Apr 24 04:50:35<br>Manuscript Received 10th Apr 24 04:50:34, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230127/dd490db5809c41dba47efd8445d736af/b6403d79e2fb4308b2f2b14ee7a06741.jpg, createdBy=1f234693702, createdName=白衣13, createdTime=Wed Apr 24 22:07:15 CST 2024, time=2024-04-24, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2203732, encodeId=e3e72203e32b5, content=请问修改后的版本要怎么上传呢,我看邮件链接里没有可以上传修订后版本的地方, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbe18212751, createdName=ms4000000471597518, createdTime=Thu May 09 20:49:01 CST 2024, time=2024-05-09, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2150842, encodeId=10cf215084251, content=审稿速度:1.0<br>偏重的研究方向:非编码RNA与肿瘤<br>经验分享:投了小cdd一个月送审返回意见后被拒,自行补了一部分实验后转投这里 6.5 投稿 6.19 小修 7.13 补了实验返回去 7.18 原则性接收 7.20 改好格式返回 7.26 接收 7.28 proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2598527487, createdName=Terryzhong15, createdTime=Tue Aug 01 23:23:27 CST 2023, time=2023-08-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2122182, encodeId=cee2212218269, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:cell death disease被拒,23号转投Cell Death Discovery,27号就预接收了,让我一度怀疑是不是投了个假杂志。。。转投的时候我没有选reprint,不是知道是不是这个原因就只有一个审稿人,而且这个审稿人还是杂志社直接指派的,还发了邮件告知我。<br><br>ditorial decision: revise, reconsidered for publication in Cell Death Discovery<br>On 27 Mar, 2023<br>Review #1 received<br>Received 26 Mar, 2023<br>1 reviewer(s) invited<br>Invitations sent on 26 Mar, 2023<br>Reviewer #1 agreed<br>On 26 Mar, 2023<br>Submission checks complete<br>On 23 Mar, 2023<br>Submitted to Cell Death Discovery<br>On 23 Mar, 2023<br>Editor assigned<br>On 23 Mar, 2023<br>Transferred to Cell Death Discovery, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221212/08d68660ec5249d4951c3cf19104981b/d48862041d924877a2d8ff1dd10a565a.jpg, createdBy=881a5215169, createdName=todmo, createdTime=Tue Mar 28 08:16:52 CST 2023, time=2023-03-28, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2202035, encodeId=546622020355f, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:已经Manuscript Under Consideration 75 天了,等的好焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=87b62464712, createdName=12425381m24暂无昵称, createdTime=Mon May 06 18:29:27 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2188846, encodeId=a2db21888463f, content=2月5号投的,当天分配编辑并Under Consideration,现在投稿17天了还没有消息,大家最近都是多久送审或者被拒的呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLv3zmjYMzwQhcQkUYuJuQtVn1K9UfSHicAAqich642LF9jozKbFliaZw0tGbw3kSTrABiaD0O5JDHXXQ/132, createdBy=215e5309360, createdName=legendaryCYP, createdTime=Fri Feb 23 10:37:35 CST 2024, time=2024-02-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2167353, encodeId=b340216e35352, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:神经系统凋亡及机制<br>经验分享:更新一下投稿时间线:<br>Manuscript Received: 7.3<br>Editor Assigned :7.3<br>Manuscript Under Consideration: 7.4<br>Manuscript Under Consideration: 8.31<br>Decision Made: 9.2<br>Decision Sent to Author: 9.8 (一审65天,等的急啊;要求11.1前返回)<br>Manuscript Received: 10.18<br>Editor Assigned: 10.18<br>Manuscript Under Consideration: 10.19<br>目前返回20天了,research square状态还是 Submission checks complete,编辑还没有返回审稿人手里,要怎么办呀?要催吗?二审一般多久呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=58, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daea8237862, createdName=ms6000000748440029, createdTime=Wed Nov 08 10:04:15 CST 2023, time=2023-11-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2100036, encodeId=1276210003694, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:请问大家,Decision sent back to author后底部有一个<br>There are action items pending. Please click on the links next to the arrows .<br>Manuscript Tasks<br> Request Appeal<br> Check Status<br>这是什么意思,通讯作者也没有收到邮件,是拒稿了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3a515544947, createdName=ms3000001031683106, createdTime=Sat Nov 12 10:28:29 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239796, encodeId=6c781239e966f, content=审稿速度:6.0<br>经验分享:under consideration80天了,谁说这个快来着。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08542281224, createdName=121c6f2dm84(暂无昵称), createdTime=Fri Aug 19 19:39:59 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157541, encodeId=1ccd215e54134, content=偏重的研究方向:细胞死亡<br>经验分享:之前投小CDD送审后被拒建议转投小小CDD。半个月后编辑将之前的审稿意见再次返回来,建议根据审稿意见修改。因为上次有一份审稿意见并不是很理想加上面临毕业,所以比较担心。有没有相同经历的朋友可以分享一下经验呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fda95570287, createdName=MM---, createdTime=Wed Sep 13 16:40:57 CST 2023, time=2023-09-13, status=1, ipAttribution=宁夏)]
    2023-08-01 Terryzhong15 来自广东省

    审稿速度:1.0
    偏重的研究方向:非编码RNA与肿瘤
    经验分享:投了小cdd一个月送审返回意见后被拒,自行补了一部分实验后转投这里 6.5 投稿 6.19 小修 7.13 补了实验返回去 7.18 原则性接收 7.20 改好格式返回 7.26 接收 7.28 proof

    7

    展开7条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2200214, encodeId=241d2200214d6, content=求好运,编辑和审稿人一生平安!!!<br><br>Manuscript Under Consideration 11th Apr 24 05:59:46<br>Editor Assigned 10th Apr 24 04:50:35<br>Manuscript Received 10th Apr 24 04:50:34, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230127/dd490db5809c41dba47efd8445d736af/b6403d79e2fb4308b2f2b14ee7a06741.jpg, createdBy=1f234693702, createdName=白衣13, createdTime=Wed Apr 24 22:07:15 CST 2024, time=2024-04-24, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2203732, encodeId=e3e72203e32b5, content=请问修改后的版本要怎么上传呢,我看邮件链接里没有可以上传修订后版本的地方, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbe18212751, createdName=ms4000000471597518, createdTime=Thu May 09 20:49:01 CST 2024, time=2024-05-09, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2150842, encodeId=10cf215084251, content=审稿速度:1.0<br>偏重的研究方向:非编码RNA与肿瘤<br>经验分享:投了小cdd一个月送审返回意见后被拒,自行补了一部分实验后转投这里 6.5 投稿 6.19 小修 7.13 补了实验返回去 7.18 原则性接收 7.20 改好格式返回 7.26 接收 7.28 proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2598527487, createdName=Terryzhong15, createdTime=Tue Aug 01 23:23:27 CST 2023, time=2023-08-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2122182, encodeId=cee2212218269, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:cell death disease被拒,23号转投Cell Death Discovery,27号就预接收了,让我一度怀疑是不是投了个假杂志。。。转投的时候我没有选reprint,不是知道是不是这个原因就只有一个审稿人,而且这个审稿人还是杂志社直接指派的,还发了邮件告知我。<br><br>ditorial decision: revise, reconsidered for publication in Cell Death Discovery<br>On 27 Mar, 2023<br>Review #1 received<br>Received 26 Mar, 2023<br>1 reviewer(s) invited<br>Invitations sent on 26 Mar, 2023<br>Reviewer #1 agreed<br>On 26 Mar, 2023<br>Submission checks complete<br>On 23 Mar, 2023<br>Submitted to Cell Death Discovery<br>On 23 Mar, 2023<br>Editor assigned<br>On 23 Mar, 2023<br>Transferred to Cell Death Discovery, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221212/08d68660ec5249d4951c3cf19104981b/d48862041d924877a2d8ff1dd10a565a.jpg, createdBy=881a5215169, createdName=todmo, createdTime=Tue Mar 28 08:16:52 CST 2023, time=2023-03-28, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2202035, encodeId=546622020355f, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:已经Manuscript Under Consideration 75 天了,等的好焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=87b62464712, createdName=12425381m24暂无昵称, createdTime=Mon May 06 18:29:27 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2188846, encodeId=a2db21888463f, content=2月5号投的,当天分配编辑并Under Consideration,现在投稿17天了还没有消息,大家最近都是多久送审或者被拒的呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLv3zmjYMzwQhcQkUYuJuQtVn1K9UfSHicAAqich642LF9jozKbFliaZw0tGbw3kSTrABiaD0O5JDHXXQ/132, createdBy=215e5309360, createdName=legendaryCYP, createdTime=Fri Feb 23 10:37:35 CST 2024, time=2024-02-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2167353, encodeId=b340216e35352, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:神经系统凋亡及机制<br>经验分享:更新一下投稿时间线:<br>Manuscript Received: 7.3<br>Editor Assigned :7.3<br>Manuscript Under Consideration: 7.4<br>Manuscript Under Consideration: 8.31<br>Decision Made: 9.2<br>Decision Sent to Author: 9.8 (一审65天,等的急啊;要求11.1前返回)<br>Manuscript Received: 10.18<br>Editor Assigned: 10.18<br>Manuscript Under Consideration: 10.19<br>目前返回20天了,research square状态还是 Submission checks complete,编辑还没有返回审稿人手里,要怎么办呀?要催吗?二审一般多久呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=58, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daea8237862, createdName=ms6000000748440029, createdTime=Wed Nov 08 10:04:15 CST 2023, time=2023-11-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2100036, encodeId=1276210003694, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:请问大家,Decision sent back to author后底部有一个<br>There are action items pending. Please click on the links next to the arrows .<br>Manuscript Tasks<br> Request Appeal<br> Check Status<br>这是什么意思,通讯作者也没有收到邮件,是拒稿了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3a515544947, createdName=ms3000001031683106, createdTime=Sat Nov 12 10:28:29 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239796, encodeId=6c781239e966f, content=审稿速度:6.0<br>经验分享:under consideration80天了,谁说这个快来着。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08542281224, createdName=121c6f2dm84(暂无昵称), createdTime=Fri Aug 19 19:39:59 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157541, encodeId=1ccd215e54134, content=偏重的研究方向:细胞死亡<br>经验分享:之前投小CDD送审后被拒建议转投小小CDD。半个月后编辑将之前的审稿意见再次返回来,建议根据审稿意见修改。因为上次有一份审稿意见并不是很理想加上面临毕业,所以比较担心。有没有相同经历的朋友可以分享一下经验呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fda95570287, createdName=MM---, createdTime=Wed Sep 13 16:40:57 CST 2023, time=2023-09-13, status=1, ipAttribution=宁夏)]
    2023-03-28 todmo 来自四川省

    审稿速度:1.0 | 投稿命中率:50.0
    经验分享:cell death disease被拒,23号转投Cell Death Discovery,27号就预接收了,让我一度怀疑是不是投了个假杂志。。。转投的时候我没有选reprint,不是知道是不是这个原因就只有一个审稿人,而且这个审稿人还是杂志社直接指派的,还发了邮件告知我。

    ditorial decision: revise, reconsidered for publication in Cell Death Discovery
    On 27 Mar, 2023
    Review #1 received
    Received 26 Mar, 2023
    1 reviewer(s) invited
    Invitations sent on 26 Mar, 2023
    Reviewer #1 agreed
    On 26 Mar, 2023
    Submission checks complete
    On 23 Mar, 2023
    Submitted to Cell Death Discovery
    On 23 Mar, 2023
    Editor assigned
    On 23 Mar, 2023
    Transferred to Cell Death Discovery

    8

    展开8条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2200214, encodeId=241d2200214d6, content=求好运,编辑和审稿人一生平安!!!<br><br>Manuscript Under Consideration 11th Apr 24 05:59:46<br>Editor Assigned 10th Apr 24 04:50:35<br>Manuscript Received 10th Apr 24 04:50:34, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230127/dd490db5809c41dba47efd8445d736af/b6403d79e2fb4308b2f2b14ee7a06741.jpg, createdBy=1f234693702, createdName=白衣13, createdTime=Wed Apr 24 22:07:15 CST 2024, time=2024-04-24, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2203732, encodeId=e3e72203e32b5, content=请问修改后的版本要怎么上传呢,我看邮件链接里没有可以上传修订后版本的地方, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbe18212751, createdName=ms4000000471597518, createdTime=Thu May 09 20:49:01 CST 2024, time=2024-05-09, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2150842, encodeId=10cf215084251, content=审稿速度:1.0<br>偏重的研究方向:非编码RNA与肿瘤<br>经验分享:投了小cdd一个月送审返回意见后被拒,自行补了一部分实验后转投这里 6.5 投稿 6.19 小修 7.13 补了实验返回去 7.18 原则性接收 7.20 改好格式返回 7.26 接收 7.28 proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2598527487, createdName=Terryzhong15, createdTime=Tue Aug 01 23:23:27 CST 2023, time=2023-08-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2122182, encodeId=cee2212218269, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:cell death disease被拒,23号转投Cell Death Discovery,27号就预接收了,让我一度怀疑是不是投了个假杂志。。。转投的时候我没有选reprint,不是知道是不是这个原因就只有一个审稿人,而且这个审稿人还是杂志社直接指派的,还发了邮件告知我。<br><br>ditorial decision: revise, reconsidered for publication in Cell Death Discovery<br>On 27 Mar, 2023<br>Review #1 received<br>Received 26 Mar, 2023<br>1 reviewer(s) invited<br>Invitations sent on 26 Mar, 2023<br>Reviewer #1 agreed<br>On 26 Mar, 2023<br>Submission checks complete<br>On 23 Mar, 2023<br>Submitted to Cell Death Discovery<br>On 23 Mar, 2023<br>Editor assigned<br>On 23 Mar, 2023<br>Transferred to Cell Death Discovery, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221212/08d68660ec5249d4951c3cf19104981b/d48862041d924877a2d8ff1dd10a565a.jpg, createdBy=881a5215169, createdName=todmo, createdTime=Tue Mar 28 08:16:52 CST 2023, time=2023-03-28, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2202035, encodeId=546622020355f, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:已经Manuscript Under Consideration 75 天了,等的好焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=87b62464712, createdName=12425381m24暂无昵称, createdTime=Mon May 06 18:29:27 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2188846, encodeId=a2db21888463f, content=2月5号投的,当天分配编辑并Under Consideration,现在投稿17天了还没有消息,大家最近都是多久送审或者被拒的呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLv3zmjYMzwQhcQkUYuJuQtVn1K9UfSHicAAqich642LF9jozKbFliaZw0tGbw3kSTrABiaD0O5JDHXXQ/132, createdBy=215e5309360, createdName=legendaryCYP, createdTime=Fri Feb 23 10:37:35 CST 2024, time=2024-02-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2167353, encodeId=b340216e35352, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:神经系统凋亡及机制<br>经验分享:更新一下投稿时间线:<br>Manuscript Received: 7.3<br>Editor Assigned :7.3<br>Manuscript Under Consideration: 7.4<br>Manuscript Under Consideration: 8.31<br>Decision Made: 9.2<br>Decision Sent to Author: 9.8 (一审65天,等的急啊;要求11.1前返回)<br>Manuscript Received: 10.18<br>Editor Assigned: 10.18<br>Manuscript Under Consideration: 10.19<br>目前返回20天了,research square状态还是 Submission checks complete,编辑还没有返回审稿人手里,要怎么办呀?要催吗?二审一般多久呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=58, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daea8237862, createdName=ms6000000748440029, createdTime=Wed Nov 08 10:04:15 CST 2023, time=2023-11-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2100036, encodeId=1276210003694, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:请问大家,Decision sent back to author后底部有一个<br>There are action items pending. Please click on the links next to the arrows .<br>Manuscript Tasks<br> Request Appeal<br> Check Status<br>这是什么意思,通讯作者也没有收到邮件,是拒稿了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3a515544947, createdName=ms3000001031683106, createdTime=Sat Nov 12 10:28:29 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239796, encodeId=6c781239e966f, content=审稿速度:6.0<br>经验分享:under consideration80天了,谁说这个快来着。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08542281224, createdName=121c6f2dm84(暂无昵称), createdTime=Fri Aug 19 19:39:59 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157541, encodeId=1ccd215e54134, content=偏重的研究方向:细胞死亡<br>经验分享:之前投小CDD送审后被拒建议转投小小CDD。半个月后编辑将之前的审稿意见再次返回来,建议根据审稿意见修改。因为上次有一份审稿意见并不是很理想加上面临毕业,所以比较担心。有没有相同经历的朋友可以分享一下经验呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fda95570287, createdName=MM---, createdTime=Wed Sep 13 16:40:57 CST 2023, time=2023-09-13, status=1, ipAttribution=宁夏)]
    2024-05-06 12425381m24暂无昵称 来自河南省

    审稿速度:3.0 | 投稿命中率:50.0
    偏重的研究方向:肿瘤
    经验分享:已经Manuscript Under Consideration 75 天了,等的好焦虑

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2200214, encodeId=241d2200214d6, content=求好运,编辑和审稿人一生平安!!!<br><br>Manuscript Under Consideration 11th Apr 24 05:59:46<br>Editor Assigned 10th Apr 24 04:50:35<br>Manuscript Received 10th Apr 24 04:50:34, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230127/dd490db5809c41dba47efd8445d736af/b6403d79e2fb4308b2f2b14ee7a06741.jpg, createdBy=1f234693702, createdName=白衣13, createdTime=Wed Apr 24 22:07:15 CST 2024, time=2024-04-24, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2203732, encodeId=e3e72203e32b5, content=请问修改后的版本要怎么上传呢,我看邮件链接里没有可以上传修订后版本的地方, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbe18212751, createdName=ms4000000471597518, createdTime=Thu May 09 20:49:01 CST 2024, time=2024-05-09, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2150842, encodeId=10cf215084251, content=审稿速度:1.0<br>偏重的研究方向:非编码RNA与肿瘤<br>经验分享:投了小cdd一个月送审返回意见后被拒,自行补了一部分实验后转投这里 6.5 投稿 6.19 小修 7.13 补了实验返回去 7.18 原则性接收 7.20 改好格式返回 7.26 接收 7.28 proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2598527487, createdName=Terryzhong15, createdTime=Tue Aug 01 23:23:27 CST 2023, time=2023-08-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2122182, encodeId=cee2212218269, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:cell death disease被拒,23号转投Cell Death Discovery,27号就预接收了,让我一度怀疑是不是投了个假杂志。。。转投的时候我没有选reprint,不是知道是不是这个原因就只有一个审稿人,而且这个审稿人还是杂志社直接指派的,还发了邮件告知我。<br><br>ditorial decision: revise, reconsidered for publication in Cell Death Discovery<br>On 27 Mar, 2023<br>Review #1 received<br>Received 26 Mar, 2023<br>1 reviewer(s) invited<br>Invitations sent on 26 Mar, 2023<br>Reviewer #1 agreed<br>On 26 Mar, 2023<br>Submission checks complete<br>On 23 Mar, 2023<br>Submitted to Cell Death Discovery<br>On 23 Mar, 2023<br>Editor assigned<br>On 23 Mar, 2023<br>Transferred to Cell Death Discovery, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221212/08d68660ec5249d4951c3cf19104981b/d48862041d924877a2d8ff1dd10a565a.jpg, createdBy=881a5215169, createdName=todmo, createdTime=Tue Mar 28 08:16:52 CST 2023, time=2023-03-28, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2202035, encodeId=546622020355f, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:已经Manuscript Under Consideration 75 天了,等的好焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=87b62464712, createdName=12425381m24暂无昵称, createdTime=Mon May 06 18:29:27 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2188846, encodeId=a2db21888463f, content=2月5号投的,当天分配编辑并Under Consideration,现在投稿17天了还没有消息,大家最近都是多久送审或者被拒的呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLv3zmjYMzwQhcQkUYuJuQtVn1K9UfSHicAAqich642LF9jozKbFliaZw0tGbw3kSTrABiaD0O5JDHXXQ/132, createdBy=215e5309360, createdName=legendaryCYP, createdTime=Fri Feb 23 10:37:35 CST 2024, time=2024-02-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2167353, encodeId=b340216e35352, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:神经系统凋亡及机制<br>经验分享:更新一下投稿时间线:<br>Manuscript Received: 7.3<br>Editor Assigned :7.3<br>Manuscript Under Consideration: 7.4<br>Manuscript Under Consideration: 8.31<br>Decision Made: 9.2<br>Decision Sent to Author: 9.8 (一审65天,等的急啊;要求11.1前返回)<br>Manuscript Received: 10.18<br>Editor Assigned: 10.18<br>Manuscript Under Consideration: 10.19<br>目前返回20天了,research square状态还是 Submission checks complete,编辑还没有返回审稿人手里,要怎么办呀?要催吗?二审一般多久呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=58, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daea8237862, createdName=ms6000000748440029, createdTime=Wed Nov 08 10:04:15 CST 2023, time=2023-11-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2100036, encodeId=1276210003694, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:请问大家,Decision sent back to author后底部有一个<br>There are action items pending. Please click on the links next to the arrows .<br>Manuscript Tasks<br> Request Appeal<br> Check Status<br>这是什么意思,通讯作者也没有收到邮件,是拒稿了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3a515544947, createdName=ms3000001031683106, createdTime=Sat Nov 12 10:28:29 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239796, encodeId=6c781239e966f, content=审稿速度:6.0<br>经验分享:under consideration80天了,谁说这个快来着。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08542281224, createdName=121c6f2dm84(暂无昵称), createdTime=Fri Aug 19 19:39:59 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157541, encodeId=1ccd215e54134, content=偏重的研究方向:细胞死亡<br>经验分享:之前投小CDD送审后被拒建议转投小小CDD。半个月后编辑将之前的审稿意见再次返回来,建议根据审稿意见修改。因为上次有一份审稿意见并不是很理想加上面临毕业,所以比较担心。有没有相同经历的朋友可以分享一下经验呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fda95570287, createdName=MM---, createdTime=Wed Sep 13 16:40:57 CST 2023, time=2023-09-13, status=1, ipAttribution=宁夏)]
    2024-02-23 legendaryCYP 来自上海

    2月5号投的,当天分配编辑并Under Consideration,现在投稿17天了还没有消息,大家最近都是多久送审或者被拒的呀?

    3

    展开3条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2200214, encodeId=241d2200214d6, content=求好运,编辑和审稿人一生平安!!!<br><br>Manuscript Under Consideration 11th Apr 24 05:59:46<br>Editor Assigned 10th Apr 24 04:50:35<br>Manuscript Received 10th Apr 24 04:50:34, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230127/dd490db5809c41dba47efd8445d736af/b6403d79e2fb4308b2f2b14ee7a06741.jpg, createdBy=1f234693702, createdName=白衣13, createdTime=Wed Apr 24 22:07:15 CST 2024, time=2024-04-24, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2203732, encodeId=e3e72203e32b5, content=请问修改后的版本要怎么上传呢,我看邮件链接里没有可以上传修订后版本的地方, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbe18212751, createdName=ms4000000471597518, createdTime=Thu May 09 20:49:01 CST 2024, time=2024-05-09, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2150842, encodeId=10cf215084251, content=审稿速度:1.0<br>偏重的研究方向:非编码RNA与肿瘤<br>经验分享:投了小cdd一个月送审返回意见后被拒,自行补了一部分实验后转投这里 6.5 投稿 6.19 小修 7.13 补了实验返回去 7.18 原则性接收 7.20 改好格式返回 7.26 接收 7.28 proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2598527487, createdName=Terryzhong15, createdTime=Tue Aug 01 23:23:27 CST 2023, time=2023-08-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2122182, encodeId=cee2212218269, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:cell death disease被拒,23号转投Cell Death Discovery,27号就预接收了,让我一度怀疑是不是投了个假杂志。。。转投的时候我没有选reprint,不是知道是不是这个原因就只有一个审稿人,而且这个审稿人还是杂志社直接指派的,还发了邮件告知我。<br><br>ditorial decision: revise, reconsidered for publication in Cell Death Discovery<br>On 27 Mar, 2023<br>Review #1 received<br>Received 26 Mar, 2023<br>1 reviewer(s) invited<br>Invitations sent on 26 Mar, 2023<br>Reviewer #1 agreed<br>On 26 Mar, 2023<br>Submission checks complete<br>On 23 Mar, 2023<br>Submitted to Cell Death Discovery<br>On 23 Mar, 2023<br>Editor assigned<br>On 23 Mar, 2023<br>Transferred to Cell Death Discovery, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221212/08d68660ec5249d4951c3cf19104981b/d48862041d924877a2d8ff1dd10a565a.jpg, createdBy=881a5215169, createdName=todmo, createdTime=Tue Mar 28 08:16:52 CST 2023, time=2023-03-28, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2202035, encodeId=546622020355f, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:已经Manuscript Under Consideration 75 天了,等的好焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=87b62464712, createdName=12425381m24暂无昵称, createdTime=Mon May 06 18:29:27 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2188846, encodeId=a2db21888463f, content=2月5号投的,当天分配编辑并Under Consideration,现在投稿17天了还没有消息,大家最近都是多久送审或者被拒的呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLv3zmjYMzwQhcQkUYuJuQtVn1K9UfSHicAAqich642LF9jozKbFliaZw0tGbw3kSTrABiaD0O5JDHXXQ/132, createdBy=215e5309360, createdName=legendaryCYP, createdTime=Fri Feb 23 10:37:35 CST 2024, time=2024-02-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2167353, encodeId=b340216e35352, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:神经系统凋亡及机制<br>经验分享:更新一下投稿时间线:<br>Manuscript Received: 7.3<br>Editor Assigned :7.3<br>Manuscript Under Consideration: 7.4<br>Manuscript Under Consideration: 8.31<br>Decision Made: 9.2<br>Decision Sent to Author: 9.8 (一审65天,等的急啊;要求11.1前返回)<br>Manuscript Received: 10.18<br>Editor Assigned: 10.18<br>Manuscript Under Consideration: 10.19<br>目前返回20天了,research square状态还是 Submission checks complete,编辑还没有返回审稿人手里,要怎么办呀?要催吗?二审一般多久呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=58, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daea8237862, createdName=ms6000000748440029, createdTime=Wed Nov 08 10:04:15 CST 2023, time=2023-11-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2100036, encodeId=1276210003694, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:请问大家,Decision sent back to author后底部有一个<br>There are action items pending. Please click on the links next to the arrows .<br>Manuscript Tasks<br> Request Appeal<br> Check Status<br>这是什么意思,通讯作者也没有收到邮件,是拒稿了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3a515544947, createdName=ms3000001031683106, createdTime=Sat Nov 12 10:28:29 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239796, encodeId=6c781239e966f, content=审稿速度:6.0<br>经验分享:under consideration80天了,谁说这个快来着。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08542281224, createdName=121c6f2dm84(暂无昵称), createdTime=Fri Aug 19 19:39:59 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157541, encodeId=1ccd215e54134, content=偏重的研究方向:细胞死亡<br>经验分享:之前投小CDD送审后被拒建议转投小小CDD。半个月后编辑将之前的审稿意见再次返回来,建议根据审稿意见修改。因为上次有一份审稿意见并不是很理想加上面临毕业,所以比较担心。有没有相同经历的朋友可以分享一下经验呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fda95570287, createdName=MM---, createdTime=Wed Sep 13 16:40:57 CST 2023, time=2023-09-13, status=1, ipAttribution=宁夏)]
    2023-11-08 ms6000000748440029 来自广东省

    审稿速度:2.0 | 投稿命中率:50.0
    偏重的研究方向:神经系统凋亡及机制
    经验分享:更新一下投稿时间线:
    Manuscript Received: 7.3
    Editor Assigned :7.3
    Manuscript Under Consideration: 7.4
    Manuscript Under Consideration: 8.31
    Decision Made: 9.2
    Decision Sent to Author: 9.8 (一审65天,等的急啊;要求11.1前返回)
    Manuscript Received: 10.18
    Editor Assigned: 10.18
    Manuscript Under Consideration: 10.19
    目前返回20天了,research square状态还是 Submission checks complete,编辑还没有返回审稿人手里,要怎么办呀?要催吗?二审一般多久呀?

    58

    展开58条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2200214, encodeId=241d2200214d6, content=求好运,编辑和审稿人一生平安!!!<br><br>Manuscript Under Consideration 11th Apr 24 05:59:46<br>Editor Assigned 10th Apr 24 04:50:35<br>Manuscript Received 10th Apr 24 04:50:34, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230127/dd490db5809c41dba47efd8445d736af/b6403d79e2fb4308b2f2b14ee7a06741.jpg, createdBy=1f234693702, createdName=白衣13, createdTime=Wed Apr 24 22:07:15 CST 2024, time=2024-04-24, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2203732, encodeId=e3e72203e32b5, content=请问修改后的版本要怎么上传呢,我看邮件链接里没有可以上传修订后版本的地方, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbe18212751, createdName=ms4000000471597518, createdTime=Thu May 09 20:49:01 CST 2024, time=2024-05-09, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2150842, encodeId=10cf215084251, content=审稿速度:1.0<br>偏重的研究方向:非编码RNA与肿瘤<br>经验分享:投了小cdd一个月送审返回意见后被拒,自行补了一部分实验后转投这里 6.5 投稿 6.19 小修 7.13 补了实验返回去 7.18 原则性接收 7.20 改好格式返回 7.26 接收 7.28 proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2598527487, createdName=Terryzhong15, createdTime=Tue Aug 01 23:23:27 CST 2023, time=2023-08-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2122182, encodeId=cee2212218269, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:cell death disease被拒,23号转投Cell Death Discovery,27号就预接收了,让我一度怀疑是不是投了个假杂志。。。转投的时候我没有选reprint,不是知道是不是这个原因就只有一个审稿人,而且这个审稿人还是杂志社直接指派的,还发了邮件告知我。<br><br>ditorial decision: revise, reconsidered for publication in Cell Death Discovery<br>On 27 Mar, 2023<br>Review #1 received<br>Received 26 Mar, 2023<br>1 reviewer(s) invited<br>Invitations sent on 26 Mar, 2023<br>Reviewer #1 agreed<br>On 26 Mar, 2023<br>Submission checks complete<br>On 23 Mar, 2023<br>Submitted to Cell Death Discovery<br>On 23 Mar, 2023<br>Editor assigned<br>On 23 Mar, 2023<br>Transferred to Cell Death Discovery, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221212/08d68660ec5249d4951c3cf19104981b/d48862041d924877a2d8ff1dd10a565a.jpg, createdBy=881a5215169, createdName=todmo, createdTime=Tue Mar 28 08:16:52 CST 2023, time=2023-03-28, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2202035, encodeId=546622020355f, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:已经Manuscript Under Consideration 75 天了,等的好焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=87b62464712, createdName=12425381m24暂无昵称, createdTime=Mon May 06 18:29:27 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2188846, encodeId=a2db21888463f, content=2月5号投的,当天分配编辑并Under Consideration,现在投稿17天了还没有消息,大家最近都是多久送审或者被拒的呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLv3zmjYMzwQhcQkUYuJuQtVn1K9UfSHicAAqich642LF9jozKbFliaZw0tGbw3kSTrABiaD0O5JDHXXQ/132, createdBy=215e5309360, createdName=legendaryCYP, createdTime=Fri Feb 23 10:37:35 CST 2024, time=2024-02-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2167353, encodeId=b340216e35352, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:神经系统凋亡及机制<br>经验分享:更新一下投稿时间线:<br>Manuscript Received: 7.3<br>Editor Assigned :7.3<br>Manuscript Under Consideration: 7.4<br>Manuscript Under Consideration: 8.31<br>Decision Made: 9.2<br>Decision Sent to Author: 9.8 (一审65天,等的急啊;要求11.1前返回)<br>Manuscript Received: 10.18<br>Editor Assigned: 10.18<br>Manuscript Under Consideration: 10.19<br>目前返回20天了,research square状态还是 Submission checks complete,编辑还没有返回审稿人手里,要怎么办呀?要催吗?二审一般多久呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=58, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daea8237862, createdName=ms6000000748440029, createdTime=Wed Nov 08 10:04:15 CST 2023, time=2023-11-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2100036, encodeId=1276210003694, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:请问大家,Decision sent back to author后底部有一个<br>There are action items pending. Please click on the links next to the arrows .<br>Manuscript Tasks<br> Request Appeal<br> Check Status<br>这是什么意思,通讯作者也没有收到邮件,是拒稿了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3a515544947, createdName=ms3000001031683106, createdTime=Sat Nov 12 10:28:29 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239796, encodeId=6c781239e966f, content=审稿速度:6.0<br>经验分享:under consideration80天了,谁说这个快来着。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08542281224, createdName=121c6f2dm84(暂无昵称), createdTime=Fri Aug 19 19:39:59 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157541, encodeId=1ccd215e54134, content=偏重的研究方向:细胞死亡<br>经验分享:之前投小CDD送审后被拒建议转投小小CDD。半个月后编辑将之前的审稿意见再次返回来,建议根据审稿意见修改。因为上次有一份审稿意见并不是很理想加上面临毕业,所以比较担心。有没有相同经历的朋友可以分享一下经验呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fda95570287, createdName=MM---, createdTime=Wed Sep 13 16:40:57 CST 2023, time=2023-09-13, status=1, ipAttribution=宁夏)]
    2022-11-12 ms3000001031683106

    审稿速度:2.0 | 投稿命中率:25.0
    经验分享:请问大家,Decision sent back to author后底部有一个
    There are action items pending. Please click on the links next to the arrows .
    Manuscript Tasks
    Request Appeal
    Check Status
    这是什么意思,通讯作者也没有收到邮件,是拒稿了吗?

    5

    展开5条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2200214, encodeId=241d2200214d6, content=求好运,编辑和审稿人一生平安!!!<br><br>Manuscript Under Consideration 11th Apr 24 05:59:46<br>Editor Assigned 10th Apr 24 04:50:35<br>Manuscript Received 10th Apr 24 04:50:34, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230127/dd490db5809c41dba47efd8445d736af/b6403d79e2fb4308b2f2b14ee7a06741.jpg, createdBy=1f234693702, createdName=白衣13, createdTime=Wed Apr 24 22:07:15 CST 2024, time=2024-04-24, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2203732, encodeId=e3e72203e32b5, content=请问修改后的版本要怎么上传呢,我看邮件链接里没有可以上传修订后版本的地方, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbe18212751, createdName=ms4000000471597518, createdTime=Thu May 09 20:49:01 CST 2024, time=2024-05-09, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2150842, encodeId=10cf215084251, content=审稿速度:1.0<br>偏重的研究方向:非编码RNA与肿瘤<br>经验分享:投了小cdd一个月送审返回意见后被拒,自行补了一部分实验后转投这里 6.5 投稿 6.19 小修 7.13 补了实验返回去 7.18 原则性接收 7.20 改好格式返回 7.26 接收 7.28 proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2598527487, createdName=Terryzhong15, createdTime=Tue Aug 01 23:23:27 CST 2023, time=2023-08-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2122182, encodeId=cee2212218269, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:cell death disease被拒,23号转投Cell Death Discovery,27号就预接收了,让我一度怀疑是不是投了个假杂志。。。转投的时候我没有选reprint,不是知道是不是这个原因就只有一个审稿人,而且这个审稿人还是杂志社直接指派的,还发了邮件告知我。<br><br>ditorial decision: revise, reconsidered for publication in Cell Death Discovery<br>On 27 Mar, 2023<br>Review #1 received<br>Received 26 Mar, 2023<br>1 reviewer(s) invited<br>Invitations sent on 26 Mar, 2023<br>Reviewer #1 agreed<br>On 26 Mar, 2023<br>Submission checks complete<br>On 23 Mar, 2023<br>Submitted to Cell Death Discovery<br>On 23 Mar, 2023<br>Editor assigned<br>On 23 Mar, 2023<br>Transferred to Cell Death Discovery, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221212/08d68660ec5249d4951c3cf19104981b/d48862041d924877a2d8ff1dd10a565a.jpg, createdBy=881a5215169, createdName=todmo, createdTime=Tue Mar 28 08:16:52 CST 2023, time=2023-03-28, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2202035, encodeId=546622020355f, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:已经Manuscript Under Consideration 75 天了,等的好焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=87b62464712, createdName=12425381m24暂无昵称, createdTime=Mon May 06 18:29:27 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2188846, encodeId=a2db21888463f, content=2月5号投的,当天分配编辑并Under Consideration,现在投稿17天了还没有消息,大家最近都是多久送审或者被拒的呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLv3zmjYMzwQhcQkUYuJuQtVn1K9UfSHicAAqich642LF9jozKbFliaZw0tGbw3kSTrABiaD0O5JDHXXQ/132, createdBy=215e5309360, createdName=legendaryCYP, createdTime=Fri Feb 23 10:37:35 CST 2024, time=2024-02-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2167353, encodeId=b340216e35352, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:神经系统凋亡及机制<br>经验分享:更新一下投稿时间线:<br>Manuscript Received: 7.3<br>Editor Assigned :7.3<br>Manuscript Under Consideration: 7.4<br>Manuscript Under Consideration: 8.31<br>Decision Made: 9.2<br>Decision Sent to Author: 9.8 (一审65天,等的急啊;要求11.1前返回)<br>Manuscript Received: 10.18<br>Editor Assigned: 10.18<br>Manuscript Under Consideration: 10.19<br>目前返回20天了,research square状态还是 Submission checks complete,编辑还没有返回审稿人手里,要怎么办呀?要催吗?二审一般多久呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=58, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daea8237862, createdName=ms6000000748440029, createdTime=Wed Nov 08 10:04:15 CST 2023, time=2023-11-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2100036, encodeId=1276210003694, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:请问大家,Decision sent back to author后底部有一个<br>There are action items pending. Please click on the links next to the arrows .<br>Manuscript Tasks<br> Request Appeal<br> Check Status<br>这是什么意思,通讯作者也没有收到邮件,是拒稿了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3a515544947, createdName=ms3000001031683106, createdTime=Sat Nov 12 10:28:29 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239796, encodeId=6c781239e966f, content=审稿速度:6.0<br>经验分享:under consideration80天了,谁说这个快来着。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08542281224, createdName=121c6f2dm84(暂无昵称), createdTime=Fri Aug 19 19:39:59 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157541, encodeId=1ccd215e54134, content=偏重的研究方向:细胞死亡<br>经验分享:之前投小CDD送审后被拒建议转投小小CDD。半个月后编辑将之前的审稿意见再次返回来,建议根据审稿意见修改。因为上次有一份审稿意见并不是很理想加上面临毕业,所以比较担心。有没有相同经历的朋友可以分享一下经验呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fda95570287, createdName=MM---, createdTime=Wed Sep 13 16:40:57 CST 2023, time=2023-09-13, status=1, ipAttribution=宁夏)]
    2022-08-19 121c6f2dm84(暂无昵称)

    审稿速度:6.0
    经验分享:under consideration80天了,谁说这个快来着。。

    13

    展开13条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2200214, encodeId=241d2200214d6, content=求好运,编辑和审稿人一生平安!!!<br><br>Manuscript Under Consideration 11th Apr 24 05:59:46<br>Editor Assigned 10th Apr 24 04:50:35<br>Manuscript Received 10th Apr 24 04:50:34, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230127/dd490db5809c41dba47efd8445d736af/b6403d79e2fb4308b2f2b14ee7a06741.jpg, createdBy=1f234693702, createdName=白衣13, createdTime=Wed Apr 24 22:07:15 CST 2024, time=2024-04-24, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2203732, encodeId=e3e72203e32b5, content=请问修改后的版本要怎么上传呢,我看邮件链接里没有可以上传修订后版本的地方, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbe18212751, createdName=ms4000000471597518, createdTime=Thu May 09 20:49:01 CST 2024, time=2024-05-09, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2150842, encodeId=10cf215084251, content=审稿速度:1.0<br>偏重的研究方向:非编码RNA与肿瘤<br>经验分享:投了小cdd一个月送审返回意见后被拒,自行补了一部分实验后转投这里 6.5 投稿 6.19 小修 7.13 补了实验返回去 7.18 原则性接收 7.20 改好格式返回 7.26 接收 7.28 proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2598527487, createdName=Terryzhong15, createdTime=Tue Aug 01 23:23:27 CST 2023, time=2023-08-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2122182, encodeId=cee2212218269, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:cell death disease被拒,23号转投Cell Death Discovery,27号就预接收了,让我一度怀疑是不是投了个假杂志。。。转投的时候我没有选reprint,不是知道是不是这个原因就只有一个审稿人,而且这个审稿人还是杂志社直接指派的,还发了邮件告知我。<br><br>ditorial decision: revise, reconsidered for publication in Cell Death Discovery<br>On 27 Mar, 2023<br>Review #1 received<br>Received 26 Mar, 2023<br>1 reviewer(s) invited<br>Invitations sent on 26 Mar, 2023<br>Reviewer #1 agreed<br>On 26 Mar, 2023<br>Submission checks complete<br>On 23 Mar, 2023<br>Submitted to Cell Death Discovery<br>On 23 Mar, 2023<br>Editor assigned<br>On 23 Mar, 2023<br>Transferred to Cell Death Discovery, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221212/08d68660ec5249d4951c3cf19104981b/d48862041d924877a2d8ff1dd10a565a.jpg, createdBy=881a5215169, createdName=todmo, createdTime=Tue Mar 28 08:16:52 CST 2023, time=2023-03-28, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2202035, encodeId=546622020355f, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:已经Manuscript Under Consideration 75 天了,等的好焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=87b62464712, createdName=12425381m24暂无昵称, createdTime=Mon May 06 18:29:27 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2188846, encodeId=a2db21888463f, content=2月5号投的,当天分配编辑并Under Consideration,现在投稿17天了还没有消息,大家最近都是多久送审或者被拒的呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLv3zmjYMzwQhcQkUYuJuQtVn1K9UfSHicAAqich642LF9jozKbFliaZw0tGbw3kSTrABiaD0O5JDHXXQ/132, createdBy=215e5309360, createdName=legendaryCYP, createdTime=Fri Feb 23 10:37:35 CST 2024, time=2024-02-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2167353, encodeId=b340216e35352, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:神经系统凋亡及机制<br>经验分享:更新一下投稿时间线:<br>Manuscript Received: 7.3<br>Editor Assigned :7.3<br>Manuscript Under Consideration: 7.4<br>Manuscript Under Consideration: 8.31<br>Decision Made: 9.2<br>Decision Sent to Author: 9.8 (一审65天,等的急啊;要求11.1前返回)<br>Manuscript Received: 10.18<br>Editor Assigned: 10.18<br>Manuscript Under Consideration: 10.19<br>目前返回20天了,research square状态还是 Submission checks complete,编辑还没有返回审稿人手里,要怎么办呀?要催吗?二审一般多久呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=58, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daea8237862, createdName=ms6000000748440029, createdTime=Wed Nov 08 10:04:15 CST 2023, time=2023-11-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2100036, encodeId=1276210003694, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:请问大家,Decision sent back to author后底部有一个<br>There are action items pending. Please click on the links next to the arrows .<br>Manuscript Tasks<br> Request Appeal<br> Check Status<br>这是什么意思,通讯作者也没有收到邮件,是拒稿了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3a515544947, createdName=ms3000001031683106, createdTime=Sat Nov 12 10:28:29 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239796, encodeId=6c781239e966f, content=审稿速度:6.0<br>经验分享:under consideration80天了,谁说这个快来着。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08542281224, createdName=121c6f2dm84(暂无昵称), createdTime=Fri Aug 19 19:39:59 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157541, encodeId=1ccd215e54134, content=偏重的研究方向:细胞死亡<br>经验分享:之前投小CDD送审后被拒建议转投小小CDD。半个月后编辑将之前的审稿意见再次返回来,建议根据审稿意见修改。因为上次有一份审稿意见并不是很理想加上面临毕业,所以比较担心。有没有相同经历的朋友可以分享一下经验呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fda95570287, createdName=MM---, createdTime=Wed Sep 13 16:40:57 CST 2023, time=2023-09-13, status=1, ipAttribution=宁夏)]
    2023-09-13 MM--- 来自宁夏

    偏重的研究方向:细胞死亡
    经验分享:之前投小CDD送审后被拒建议转投小小CDD。半个月后编辑将之前的审稿意见再次返回来,建议根据审稿意见修改。因为上次有一份审稿意见并不是很理想加上面临毕业,所以比较担心。有没有相同经历的朋友可以分享一下经验呀?

    2

    展开2条回复
共500条页码: 1/50页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分